ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO038

Expression of CD71 Mesangial IgA1 Receptor Predicts Progression of IgA Nephropathy

Session Information

Category: Glomerular

  • 1001 Glomerular: Basic/Experimental Immunology and Inflammation

Authors

  • Jhee, Jong Hyun, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
  • Park, Seohyun, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
  • An, Seong yeong, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
  • Nam, Ki Heon, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
  • Nam, Boyoung, College of Medicine, Severance Biomedical Science Institute, Brain Korea 21 PLUS, Yonsei University, Seoul, Korea (the Republic of)
  • Wu, Meiyan, College of Medicine, Severance Biomedical Science Institute, Brain Korea 21 PLUS, Yonsei University, Seoul, Korea (the Republic of)
  • Kang, Sukyung, College of Medicine, Severance Biomedical Science Institute, Brain Korea 21 PLUS, Yonsei University, Seoul, Korea (the Republic of)
  • Choi, Arum, College of Medicine, Severance Biomedical Science Institute, Brain Korea 21 PLUS, Yonsei University, Seoul, Korea (the Republic of)
  • Yoo, Tae-Hyun, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
  • Kang, Shin-Wook, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
  • Han, Seung Hyeok, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea (the Republic of)
Background

The transferrin receptor (CD71) is known as a receptor for IgA1 on mesangial cells and plays a key role in the pathogenesis of IgA nephropathy. However, little is known about the association between clinical outcomes and the level of CD71 expression.

Methods

We studied the clinical implication of mesangial CD71 in 282 patients with biopsy-proven IgAN between 2005 and 2014. Glomeruli were obtained from biopsy tissues by manual microdissection. The expression of glomerular CD71 was determined by real-time polymerase chain reaction. Disease progression was defined as a ≥ 30% decline in estimated glomerular filtration rate (eGFR).

Results

During a mean follow up of 51.6 months, 40 (14.2%) patients developed disease progression. The mRNA expression of CD71 was significantly higher in progressors than in non-progressors (P = 0.01). Immunnohistochemial study also confirmed the higher expression of CD71 in the former. In a multivariable Cox model adjusted for confounders, enhanced transcript level of CD71 was significantly associated with an increased risk of disease progression (P = 0.018). Furthermore, CD71 expression level independently predicted the development of persistent proteinuria of ≥ 1 g/g creatinine (P = 0.003). Among 4 components of the Oxford classification, only M1 score was significantly associated with a higher transcript level of CD71.

Conclusion

We showed that glomerular CD 71 expression is significantly associated with various clinically important parameters in IgA nephropathy. This finding suggests that incorporation of CD71 into risk stratification is helpful in determination of adverse outcomes.